Complete Clinical Responses to Neoadjuvant Chemotherapy for Uterine Serous Carcinoma

Three cases of serous carcinoma of the uterus with radiographically documented widespread metastases are presented. Following confirmation of histopathology, all were treated with a standard regimen of carboplatin and paclitaxel for eight courses with complete resolution of distant metastases on CT...

Full description

Saved in:
Bibliographic Details
Published in:Gynecologic oncology 1999-04, Vol.73 (1), p.140-144
Main Authors: Price, Fredric V., Amin, Rajnikant M., Sumkin, Jules
Format: Article
Language:English
Subjects:
Adult
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Carboplatin - administration & dosage
chemotherapy
Chemotherapy, Adjuvant
endometrial cancer
Female
Female genital diseases
Gynecology. Andrology. Obstetrics
Humans
Medical sciences
Middle Aged
Neoplasm Metastasis
Paclitaxel - administration & dosage
Tumors
uterine cancer
Uterine Neoplasms - drug therapy
Uterine Neoplasms - pathology
Uterine Neoplasms - surgery
uterine serous carcinoma
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Three cases of serous carcinoma of the uterus with radiographically documented widespread metastases are presented. Following confirmation of histopathology, all were treated with a standard regimen of carboplatin and paclitaxel for eight courses with complete resolution of distant metastases on CT scan prior to postchemotherapy surgical exploration. Two patients had gross disease at laparotomy, and one had only microscopic tumor found in the uterine specimen. This experience offers rationale for treatment of patients with widely metastatic uterine serous carcinoma or other relative contraindications to surgery with primary carboplatin and paclitaxel. In addition, we believe this experience supports the hypothesis that this regimen may result in prolonged disease-free survival when employed as postsurgical adjuvant therapy.
ISSN:0090-8258
1095-6859
DOI:10.1006/gyno.1998.5303